Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Risk Reduction: early-phase trial registry

2 of 14 indexed Risk Reduction trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,230 of 28,707 conditions by registered trial count.

14 US clinical trials · 2 currently recruiting · #1,230 of 28,707 conditions by registered trial count

Risk Reduction: 14 US clinical trials tracked, 2 recruiting.

Risk Reduction is the subject of 14 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Florida State University, running 2 of these trials.

Enrollment posture brief

Registry condition risk-reduction

OPEN 2 | RECR 14% | LATE 1 | EARLY 2 | RANK #1230 | SPON 2

Nearest open-share peer: Adverse Drug Events (14% recruiting · 7 trials)

Acute Respiratory Failure35.7%Adherence, Medication35.7%Acromegaly28.6%Risk Reduction (this)14%Abscess7.1%
Open-enrollment share among volume-matched conditions near Risk Reduction

Risk Reduction lists 2 open slots (14% of 14 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Risk Reduction on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Risk Reduction is recruiting below its size-band peers.

    2 of 14 indexed trials (14.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Risk Reduction trials is spread across many organizations.

    Florida State University accounts for 2 of 14 trials (14.3%). 12 distinct sponsors appear on at least one study for this condition label.

  3. Typical Risk Reduction enrolment sits around 148 participants.

    Median target enrolment is 148 among the 14 trials that report a genuine target (sentinel values excluded). 4 of those (28.6%) plan for fewer than 100 participants.

  4. Risk Reduction research is mostly interventional.

    13 interventional and 1 observational studies make up this index (92.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 21Phase 41

Open and recent trials

14 total, page 1 of 1

RECRUITING 2,300 participants

Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer

San Raffaele University

NCT05732623

RECRUITING Phase 4 150 participants

Blood Donor CVD 5000

University of Maryland, Baltimore

NCT03971669

ACTIVE NOT RECRUITING NA 1,200 participants

Tennessee Youth Prepared for Success

Centerstone Research Institute

NCT06001892

ACTIVE NOT RECRUITING Phase 2 120 participants

Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens

University of Kansas Medical Center

NCT04821141

COMPLETED NA 43,225 participants

Efficacy of Communication Modalities for Promoting Flu Shots

Geisinger Clinic

NCT05509270

COMPLETED NA 233 participants

Building Stronger Allies

Florida State University

NCT03571750

COMPLETED NA 196 participants

Prevention and Risk: Treatment With a New Emphasis on Relationships

Hunter College of City University of New York

NCT03396367

COMPLETED NA 148 participants

Acceptability, Feasibility, and Preliminary Impact of a Web-based, HIV Prevention Toolkit With Cisgender Male Couples in Lima, Peru

Florida International University

NCT05873855

COMPLETED NA 134 participants

Nature and Health: How Does Lifestyle and Environment Affect Health and Wellness

Stanford University

NCT06001697

COMPLETED NA 105 participants

Electronic Confirmed Versus Conventional Consenting Process: A Randomized Controlled Trial

The University of Texas Medical Branch, Galveston

NCT03510260

COMPLETED Phase 1 96 participants

Salmonella Conjugates CVD 1000: Study of Responses to Vaccination With Trivalent Invasive Salmonella Disease Vaccine

University of Maryland, Baltimore

NCT03981952

COMPLETED NA 80 participants

Rural Chronic Disease Risk Reduction

Florida State University

NCT05611580

COMPLETED NA 63 participants

PrEP Point-of-Care Brief-Intervention for Adherence Among Young Men Who Have Sex With Men

University of California, San Francisco

NCT05353283

COMPLETED NA 30 participants

Monitoring Environmental Exposures and Behavioral Change

University of Utah

NCT05338242

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 1
Phase 4 1

Named interventions

Most-linked intervention names on Risk Reduction records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Real-Time Exposure Feedback Device
1 trials
Education Intervention Behavioral
1 trials
PARTNER Behavioral
1 trials
Trivalent Invasive Salmonella Disease Vaccine (highest, well-tolerated dose among Cohorts A-C) Biological
1 trials
Trivalent Invasive Salmonella Disease Vaccine (25 µg) Biological
1 trials
Trivalent Invasive Salmonella Disease Vaccine (12 µg) Biological
1 trials
Trivalent Invasive Salmonella Disease Vaccine (6.25 µg) Biological
1 trials
Chronic Disease Risk Reduction Behavioral
1 trials

US sites by state

Facility locations filed on Risk Reduction trials. A trial with sites in several states counts in each.

Pennsylvania 2 trials
Maryland 2 trials
Illinois 2 trials
Florida 2 trials
California 2 trials
Utah 1 trials
Texas 1 trials
Tennessee 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Risk Reduction page

14 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Risk Reduction condition card totals 14 registered trials; most-linked intervention Real-Time Exposure Feedback; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.